This article originally appeared as part of The Vendor Edge series on LinkedIn. This is an expanded and updated version for kieranengels.com.
Poor governance creates hidden costs that bleed across clinical programs. Scope drift accumulates silently. Financial leakage happens in budget gaps and contract overages nobody tracks. Rework multiplies in handoff failures and unclear ownership. Leadership fatigue sets in when decisions are questioned and re-made. Delivery slows because priorities shift without clear rationale. Governance breaks at four distinct levels: the board sets strategy but misses execution reality; executives make decisions without full vendor context; operations clash with vendor capabilities; vendors operate without clear accountability. The fix requires governance as a design system: clarity in strategy, explicit priorities, documented assumptions, and agreed conditions before execution begins.
Key Takeaways
Key Takeaways
- Poor governance creates four hidden costs: scope drift (silent accumulation), financial leakage (budget gaps), invisible rework (unclear handoffs), leadership fatigue (constant re-decision), and slowed delivery (shifting priorities without rationale).
- Governance breaks at the board level when strategy disconnects from execution reality, at the executive level when decisions lack vendor context, at operations when priorities clash with capabilities, and at the vendor level when accountability is absent.
- Kieran Engels and Seuss+ work with biotech teams to build governance systems that create clarity in strategy, explicit priorities, documented assumptions, and agreed conditions before execution begins.
- Effective governance prevents scope creep by establishing clear decision criteria and approval pathways, protecting timelines and budgets from silent erosion.
- Governance is not bureaucracy. It is the design system that enables faster, more confident decision-making by reducing ambiguity and rework.
Understanding the Four Levels of Governance Breakdown
Governance failures rarely announce themselves. They accumulate in quiet ways. A board approves a vendor selection based on operational assumptions that turn out to be wrong. Executives make decisions about trial timelines without consulting the vendors who will execute them. Operations teams implement processes that vendors cannot support. Vendors operate without clear accountability for decisions they influence.
Each level breaks independently. When all four break together, the result is a program that runs slower, costs more, and delivers less than promised.
Four Levels of Governance Breakdown
| Level | Where It Breaks | Hidden Cost | Governance Fix |
| Board | Strategy disconnects from execution capability | Wrong vendor selection, poor fit | Operational due diligence before selection |
| Executive | Decisions made without vendor context | Timeline commitments vendors cannot meet | Vendor input on feasibility before decision |
| Operational | Processes designed without vendor capability input | Rework, scope drift, budget overages | Clear process definition with vendor sign-off |
| Vendor | Vendors operate without clear accountability | Finger-pointing, unclear ownership | Explicit vendor accountability in contracts |
The Cost of Silent Scope Drift
Scope drift happens in the gaps between intent and execution. A vendor delivers more than contracted because nobody said no. A trial expands in scope because the decision to expand happened in a meeting without formal approval. Budget shifts because assumptions about effort were never documented. The accumulated effect is a program that costs 20% more and takes 20% longer than planned, but nobody can point to a single decision that caused it.
Building Governance into Strategy
The fix is not more meetings or more approvals. The fix is clarity. Kieran Engels works with sponsors to define strategy with operational precision. What are we building? What are we not building? What are we assuming about vendor capability? What happens if those assumptions break?
Seuss+ helps teams document these decisions and create governance systems that prevent them from being silently eroded. Decision criteria become explicit. Approval pathways become clear. Accountability becomes assigned.
Governance is not bureaucracy. It is the design system that enables faster, more confident decision-making by reducing ambiguity and rework.
Key Industry Data
The global CRO market reached $79.5 billion in 2023, with the top five players controlling more than 35% of market share. (Source: Grand View Research, IQVIA)
63% of new trial starts now come from emerging biotech companies that often lack internal infrastructure to evaluate CRO capability. (Source: IQVIA)
Between 50% and 60% of all clinical trial activities are outsourced to CROs globally, making selection the single highest impact operational decision. (Source: IQVIA)
A single protocol amendment adds approximately three months and $500,000 or more in unbudgeted costs, often driven by misalignment between sponsor expectations and CRO delivery models. (Source: Tufts CSDD)
Daily trial delays cost sponsors $600,000 to $8 million per day, and mid trial CRO transitions compound those losses significantly. (Source: Tufts CSDD)
Frequently Asked Questions
Governance sets the framework and decision criteria. Micromanagement controls every execution detail. Good governance gives teams clarity about what matters and autonomy in how to deliver it. It removes ambiguity without removing authority.
Look for patterns. Decisions are questioned and re-made. Scope expands without formal approval. Budget overages appear in retrospect, not during planning. Vendors complain about unclear expectations. Teams spend time defending decisions instead of executing. These signals indicate governance has broken.
Yes, but it requires honesty about the current state. Governance added mid-program must first establish clarity about what has been promised, what can be delivered, and what assumptions have been made. Then it creates going-forward discipline around decisions.
That is crucial information. It means the vendor is not a fit for the program, or your requirements are unrealistic. Better to learn this during governance design than during execution. It prevents hidden failures later.
Clear governance accelerates decision-making because decisions do not need to be re-litigated. Teams know the criteria, the authority, and the timeline. This reduces the back-and-forth that typically slows programs down.
About the Author
Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.
